New drug combo shows promise for Tough-to-Treat head and neck cancer

NCT ID NCT03818061

Completed Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Apr 26, 2026 · Last updated May 20, 2026 · Updated 5 times

Summary

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 33 adults with advanced head and neck cancer that had already been treated with platinum-based chemotherapy. The goal was to see if the combo could shrink or control tumors. The approach aims to boost the immune system and cut off tumor blood supply, but it is not a cure and ongoing management is expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Léon Bérard

Lyon, 69373, France
Centre Paul Strauss

Strasbourg, 67065, France
Clinique Mutualiste de l'Estuaire

Saint-Nazaire, 44606, France
Institut Claudius Regaud

Toulouse, 31059, France
Institut Curie

Paris, 75005, France

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK NEOPLASMS